7.25
3.20%
-0.24
XBiotech Inc stock is currently priced at $7.25, with a 24-hour trading volume of 26,447.
It has seen a -3.20% decreased in the last 24 hours and a -5.48% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $7.42 pivot point. If it approaches the $7.24 support level, significant changes may occur.
Previous Close:
$7.49
Open:
$7.53
24h Volume:
26,447
Market Cap:
$220.82M
Revenue:
$4.01M
Net Income/Loss:
$-24.56M
P/E Ratio:
-7.7128
EPS:
-0.94
Net Cash Flow:
$-19.09M
1W Performance:
-12.76%
1M Performance:
-5.48%
6M Performance:
+84.95%
1Y Performance:
+42.30%
XBiotech Inc Stock (XBIT) Company Profile
Name
XBiotech Inc
Sector
Industry
Phone
512-386-2900
Address
8201 East Riverside Drive, Building 4 Suite 100, Austin, TX
XBiotech Inc Stock (XBIT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-14-19 | Initiated | Piper Jaffray | Overweight |
Apr-21-17 | Downgrade | Noble Financial | Buy → Hold |
Jun-28-16 | Reiterated | Noble Financial | Buy |
XBiotech Inc Stock (XBIT) Latest News
Market Insight: XBiotech Inc (XBIT)'s Notable Drop, Closing at 7.37 – DWinneX - The Dwinnex
The Dwinnex
XBiotech (NASDAQ:XBIT) Shares Cross Below 50-Day Moving Average of $8.40 - MarketBeat
MarketBeat
XBiotech (NASDAQ:XBIT) Stock Crosses Below Fifty Day Moving Average of $8.40 - Defense World
Defense World
XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus - Yahoo Movies UK
Yahoo Movies UK
(XBIT) Long Term Investment Analysis - Stock Traders Daily
Stock Traders Daily
XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus - Yahoo Movies UK
Yahoo Movies UK
XBiotech Inc Stock (XBIT) Financials Data
XBiotech Inc (XBIT) Revenue 2024
XBIT reported a revenue (TTM) of $4.01 million for the quarter ending December 31, 2022, a -78.20% decline year-over-year.
XBiotech Inc (XBIT) Net Income 2024
XBIT net income (TTM) was -$24.56 million for the quarter ending December 31, 2023, a +25.36% increase year-over-year.
XBiotech Inc (XBIT) Cash Flow 2024
XBIT recorded a free cash flow (TTM) of -$19.09 million for the quarter ending December 31, 2023, a -23.87% decrease year-over-year.
XBiotech Inc (XBIT) Earnings per Share 2024
XBIT earnings per share (TTM) was -$0.82 for the quarter ending December 31, 2023, a +24.07% growth year-over-year.
About XBiotech Inc
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Cap:
|
Volume (24h):